Youcare Pharmaceutical (SH:688658) 生物世界·2025-12-03 04:04Core Viewpoint - The article discusses a promising new treatment for chronic hepatitis B virus (HBV) infection, highlighting the potential of the siRNA drug KC13-M2G2 to achieve functional cure, outperforming existing therapies [3][4][7]. Group 1: Background on HBV - Approximately 325 million people globally are chronically infected with HBV, leading to nearly 1 million deaths annually despite the availability of effective vaccines [2]. - Chronic HBV infection poses significant risks, including progressive liver disease and is responsible for nearly half of liver cancer cases [2]. Group 2: Research Findings - The research published by the team from悦康药业 in Nature Communications presents KC13-M2G2, an siRNA drug targeting the HBV S region, which aims to significantly suppress HBsAg levels and restore host immunity [3][6]. - KC13-M2G2 demonstrated strong antiviral efficacy against all HBV genotypes in vitro and showed rapid and sustained reductions in HBsAg and HBV DNA levels in multiple mouse models, with serological conversion of HBsAb [7]. - In toxicology studies on rats and crabs monkeys, KC13-M2G2 exhibited satisfactory biosafety, indicating its potential for clinical application [7].